{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:50:25Z","timestamp":1784055025187,"version":"3.55.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.bbcan.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T04:32:28Z","timestamp":1370320348000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["CTLA-4 blockade and the renaissance of cancer immunotherapy"],"prefix":"10.1016","volume":"1836","author":[{"given":"Simone","family":"Mocellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Nitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2013.05.003_bb0005","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2741\/1698","article-title":"Cancer vaccines: the challenge of developing an ideal tumor killing system","volume":"10","author":"Mocellin","year":"2005","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/1547691X.2012.685527","article-title":"The role of antigen-specific and non-specific immunotherapy in the treatment of cancer","volume":"9","author":"Monjazeb","year":"2012","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0065-230X(06)95005-2","article-title":"Clinical results of vaccine therapy for cancer: learning from history for improving the future","volume":"95","author":"Choudhury","year":"2006","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(04)01610-9","article-title":"Part I: vaccines for solid tumours","volume":"5","author":"Mocellin","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cbr.2010.0902","article-title":"Cancer immunotherapy","volume":"26","author":"Dillman","year":"2011","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.33077","article-title":"Interleukin-2: clinical applications","volume":"29","author":"Atkins","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0040","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.seminoncol.2006.12.004","article-title":"Immunotherapeutic strategies for high-risk bladder cancer","volume":"34","author":"Sharma","year":"2007","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0050","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nrurol.2012.106","article-title":"Cancer immunotherapy: a paradigm shift for prostate cancer treatment","volume":"9","author":"Karan","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gde.2007.12.007","article-title":"Immune surveillance: a balance between protumor and antitumor immunity","volume":"18","author":"Ostrand-Rosenberg","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1471-4906(03)00116-9","article-title":"Tumors as elusive targets of T-cell-based active immunotherapy","volume":"24","author":"Marincola","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0075","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00262-011-1012-8","article-title":"Camouflage and sabotage: tumor escape from the immune system","volume":"60","author":"Poschke","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0b013e3181837276","article-title":"Suppressive influences in the immune response to cancer","volume":"32","author":"Bronte","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/med.20110","article-title":"Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines","volume":"28","author":"Mocellin","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/neuonc\/noq142","article-title":"Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study","volume":"13","author":"Bogdahn","year":"2011","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2003.11.001","article-title":"The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle","volume":"15","author":"Mocellin","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/156800909787581015","article-title":"Nitric oxide: cancer target or anticancer agent?","volume":"9","author":"Mocellin","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"issue":"2","key":"10.1016\/j.bbcan.2013.05.003_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cytogfr.2013.01.003","article-title":"Coinhibitory molecules in cancer biology and therapy","volume":"24","author":"Mocellin","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0120","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0125","first-page":"133","article-title":"Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?","volume":"2","author":"Reilly","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.immunol.19.1.375","article-title":"The immunological synapse","volume":"19","author":"Bromley","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-065X.2007.00526.x","article-title":"The molecular makeup and function of regulatory and effector synapses","volume":"218","author":"Reichardt","year":"2007","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses","volume":"20","author":"Carreno","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T cell anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0150","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri1349","article-title":"Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity","volume":"4","author":"Chen","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.20.100301.064828","article-title":"Antigen presentation and T cell stimulation by dendritic cells","volume":"20","author":"Guermonprez","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0160","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0165","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/ni1141","article-title":"Plasmacytoid dendritic cells in immunity","volume":"5","author":"Colonna","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0065-230X(04)92002-7","article-title":"Tumor-host immune interactions and dendritic cell dysfunction","volume":"92","author":"Yang","year":"2004","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0175","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1498","article-title":"Mechanisms and functional significance of tumour-induced dendritic-cell defects","volume":"4","author":"Gabrilovich","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0180","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1201-1339","article-title":"Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells","volume":"7","author":"Zou","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1385\/IR:32:1-3:155","article-title":"CD25+ CD4+ regulatory T-cells in cancer","volume":"32","author":"Linehan","year":"2005","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0195","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0200","doi-asserted-by":"crossref","first-page":"F5","DOI":"10.1084\/jem.193.2.F5","article-title":"Differentiation of T regulatory cells by immature dendritic cells","volume":"193","author":"Roncarolo","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0205","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2013preclinical background: CTLA-4 and PD-1 blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0210","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood-2012-02-412510","article-title":"Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention","volume":"120","author":"Norde","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2014CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0220","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0225","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0230","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0235","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.189.2.435","article-title":"B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)","volume":"189","author":"Mandelbrot","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0245","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0250","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0255","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0260","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0265","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nature05543","article-title":"Foxp3-dependent programme of regulatory T-cell differentiation","volume":"445","author":"Gavin","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0270","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","article-title":"Mechanisms of foxp3+ T regulatory cell-mediated suppression","volume":"30","author":"Shevach","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0275","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0280","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.4049\/jimmunol.173.4.2866","article-title":"Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity","volume":"173","author":"Vasu","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"Peggs","year":"2006","journal-title":"Curr. Opin. Immunol."},{"issue":"Suppl. 4","key":"10.1016\/j.bbcan.2013.05.003_bb0290","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","article-title":"The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation","volume":"13","author":"Wolchok","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0295","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0300","first-page":"4036","article-title":"Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages","volume":"57","author":"Yang","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0305","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1517\/14656566.2011.629187","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma","volume":"12","author":"Wang","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0310","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.95.17.10067","article-title":"CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma","volume":"95","author":"Hurwitz","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0315","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/1097-0215(20000815)87:4<539::AID-IJC13>3.0.CO;2-E","article-title":"B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma","volume":"87","author":"Van Ginderachter","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0320","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0325","doi-asserted-by":"crossref","first-page":"15074","DOI":"10.1073\/pnas.96.26.15074","article-title":"Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy","volume":"96","author":"Kwon","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0330","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-07-0813","article-title":"Cytotoxic T-lymphocyte-associated antigen-4","volume":"13","author":"Hodi","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0335","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0340","first-page":"2444","article-title":"Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade","volume":"60","author":"Hurwitz","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0345","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.vaccine.2003.10.048","article-title":"CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems","volume":"22","author":"Gregor","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0350","first-page":"7483","article-title":"Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity","volume":"63","author":"Santulli-Marotto","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0355","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.194.4.481","article-title":"Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy","volume":"194","author":"van Elsas","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0360","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.seminoncol.2010.09.010","article-title":"Clinical development of the anti-CTLA-4 antibody tremelimumab","volume":"37","author":"Ribas","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0365","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0370","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-08-0783","article-title":"Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0375","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-11-0407","article-title":"CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans","volume":"17","author":"Huang","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0380","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0385","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0390","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2013.05.003_bb0395","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0400","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2011.37.5394","article-title":"Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma","volume":"30","author":"Tarhini","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0405","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00262-011-1193-1","article-title":"Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer","volume":"61","author":"McNeel","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0410","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0415","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0420","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0425","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0430","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.seminoncol.2010.09.006","article-title":"Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications","volume":"37","author":"Calabro","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0435","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0440","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials","volume":"4","author":"Eigentler","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0445","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0450","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0455","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2012.0037","article-title":"Systemic therapy for metastatic melanoma in 2012: dawn of a new era","volume":"10","author":"Bhatia","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0460","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nrc3153","article-title":"Novel cancer immunotherapy agents with survival benefit: recent successes and next steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0465","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","article-title":"New drugs in melanoma: it's a whole new world","volume":"47","author":"Eggermont","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0470","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrclinonc.2011.119","article-title":"Targeted therapies: improved outcomes for patients with metastatic melanoma","volume":"8","author":"Sondak","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0475","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0480","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0485","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1200\/jco.2011.29.15_suppl.8583","article-title":"Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma","volume":"29","author":"Ibrahim","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0490","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0495","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0500","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0505","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0510","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0515","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2006.01.026","article-title":"RECIST revisited: a review of validation studies on tumour assessment","volume":"42","author":"Therasse","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0520","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0525","doi-asserted-by":"crossref","first-page":"A9041","DOI":"10.1200\/jco.2009.27.15_suppl.9041","article-title":"Effect of ipilimumab at 10mg\/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels","volume":"27","author":"Smylie","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0530","doi-asserted-by":"crossref","first-page":"A8581","DOI":"10.1200\/jco.2011.29.15_suppl.8581","article-title":"Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases","volume":"29","author":"Heller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0535","doi-asserted-by":"crossref","first-page":"A2555","DOI":"10.1200\/jco.2010.28.15_suppl.2555","article-title":"CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes","volume":"28","author":"Yang","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0540","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0545","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0550","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00262-011-1124-1","article-title":"Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma","volume":"61","author":"Zhou","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0555","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2014revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0560","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0565","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 8","key":"10.1016\/j.bbcan.2013.05.003_bb0570","doi-asserted-by":"crossref","first-page":"viii15","DOI":"10.1093\/annonc\/mds258","article-title":"How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma","volume":"23","author":"Wolchok","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0575","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0580","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0585","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/j.seminoncol.2010.09.009","article-title":"Anti-CTLA-4 antibody adjuvant therapy in melanoma","volume":"37","author":"Eggermont","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0590","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djs033","article-title":"Therapeutic cancer vaccines: current status and moving forward","volume":"104","author":"Schlom","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0595","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/CJI.0b013e3182562d59","article-title":"Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors","volume":"35","author":"Agarwalla","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0600","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0605","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0610","doi-asserted-by":"crossref","first-page":"e19499","DOI":"10.1371\/journal.pone.0019499","article-title":"Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production","volume":"6","author":"Curran","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0615","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1016\/j.vaccine.2010.07.066","article-title":"Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model","volume":"28","author":"Sorensen","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0620","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1172\/JCI61931","article-title":"Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects","volume":"122","author":"Ruocco","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2013.05.003_bb0625","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.imbio.2011.07.005","article-title":"Ipilimumab (Yervoy) and the TGN1412 catastrophe","volume":"217","author":"Bakacs","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.bbcan.2013.05.003_bb0630","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.immuni.2008.04.003","article-title":"CD28 superagonists: what makes the difference in humans?","volume":"28","author":"Schraven","year":"2008","journal-title":"Immunity"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X13000358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X13000358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T17:35:48Z","timestamp":1645637748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X13000358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0304419X13000358"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2013.05.003","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CTLA-4 blockade and the renaissance of cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2013.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}